(S025) Discovery and Validation of Predictive Factors for Safety Incident Reports in Patients Receiving Radiation Therapy: Comparative Results From a Large Safety Variance Database

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

We determined several patient and treatment-specific characteristics that predicted for treatment incident events. Children were more susceptible to incident alerts, possibly related to increased staff vigilance or more frequent use of complex modalities. Patients with head and neck tumors, greater number of fractions, treatment on protocol, and use of IMRT also predicted for incidents.

Shereef M. Elnahal, MD, MBA, Amanda Blackford, SCM, Eric C. Ford, PhD, Annette N. Souranis, Valerie Briner, Koren Smith, PhD, Todd R. McNutt, PhD, Theodore L. Deweese, MD, Jean Wright, MD, Stephanie A. Terezakis, MD; Johns Hopkins University School of Medicine; Department of Radiation Oncology, University of Washington; Department of Radiation Oncology, Johns Hopkins Hospital

OBJECTIVES: Patient safety is a vital concern in radiotherapy, but little is known about the factors that predict patients at risk for safety incidents. We aimed to: a) describe patients who have experienced safety incident reports; and b) compare them with a cohort without events to identify predictive factors and build a nomogram tool to identify patients at risk.

MATERIALS AND METHODS: We used our institution’s radiation treatment safety incident reporting system to build a database of patients who experienced events from January 2011–October 2014. Patient and treatment-specific data were reviewed from our institution’s radiation management software program for a random selection of patients with events in our reporting system. A control group of sequential patients in 2014 was generated for comparison. Summary statistics, likelihood ratios, and mixed-effect logistic regression models were used for group comparisons.

RESULTS: The safety incident group comprised 1050 events. Errors in treatment planning (eg, incorrect planning target volume [PTV] margins submitted) (35.2%) and documentation (eg, wrong patient name denoted) (34.9%) were the most common incident types, followed by communication (17.5%) and treatment delivery (12.4%). Several clinical and treatment-specific factors correlated with safety reports. Incidents were much more frequently reported in minors (age < 18 yr) than in adults (25.3% vs 5.4%; P < .001). Patients with head and neck (16% vs 8%; P < .001) and breast (20% vs 15%; P = .03) primaries were more frequently associated with an incident. Larger tumors (19% vs 11% had T4 lesions; P = .02), a greater mean number of fractions (24 vs 20; P = .02), and cases on protocol (9% vs 5%; P = .005) or with intensity-modulated radiation therapy (IMRT)/image-guided IMRT (IGMRT) (52% vs 43%; P = .001) were associated with incident events. Of note, IMRT was used in 70.5% of minors treated. Other independently associated factors were found in patients with T4 tumors (19.5% protocol, 50.7% head and neck, mean of 24 fractions). On multivariate analysis, dose per fraction, head and neck cases, pediatric patients, protocol enrollment, and average pain score independently predicted for safety events.

CONCLUSIONS: We determined several patient and treatment-specific characteristics that predicted for treatment incident events. Children were more susceptible to incident alerts, possibly related to increased staff vigilance or more frequent use of complex modalities. Patients with head and neck tumors, greater number of fractions, treatment on protocol, and use of IMRT also predicted for incidents. Independently predictive variables have been built into a nomogram that will be validated in a prospective dataset, the results of which will be available at the time of the meeting. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content